The MedDRA Management Board recognises that there is a need for interoperability with other terminologies. The MSSO is tasked with developing necessary mappings to MedDRA and providing ongoing support and maintenance of these mappings. Currently this includes:
WHO-ART Bridge - A collaborative effort has been undertaken between the ICH and the Uppsala Monitoring Centre (UMC) of the World Health Organization (WHO) to implement MedDRA in the WHO global safety database allowing entry and retrieval of information in either MedDRA or WHO-ART. A mapping bridge is updated by WHO and ICH (through the MSSO), to convert WHO-ART coded data into MedDRA, allowing WHO-ART users to readily convert their data and use MedDRA.
CTCAE - Originally, a mapping was developed between the Common Terminology Criteria for Adverse Events (CTCAE) and MedDRA. In 2009 a collaborative effort was also undertaken to review and revise the CTCAE and to use MedDRA terms directly. Since CTCAE Version 4.0 (May 2009), all the terms in the terminology, used and maintained by the US National Cancer Institute (NCI) of the National Institute of Health (NIH), are themselves LLTs of MedDRA.
NICHD Pediatric Adverse Events Terminology - The National Institute of Child Health and Human Development (NICHD), the National Cancer Institute Enterprise Vocabulary Services (NCI EVS), and the MSSO jointly developed a mapping of the NICHD Pediatric Adverse Event Terminology to MedDRA to support the reporting of adverse events in the pediatric population.
There is increasing interest among regulators and industry to improve safety signal detection through the application of active surveillance methods and the collection of data from new sources including Electronic Healthcare Records (EHRs).
The MedDRA Management Board regularly considers collaboration with several pharmacovigilance initiatives and other terminologies in other domains for mapping needs.